UK Glaxo Pandemix h1n1 vaccine
Posted: Thu Dec 03, 2009 8:53 pm
squalene, polysorbate 80 and mercury
bad to the bone
Sheri
http://www.emea.europa.eu/humandocs/PDF ... -17-en.pdf
GSK's proprietary adjuvant system AS03, (squalene-based oil-in-water emulsion)
NOTE: The adjuvant is added to the antigen vial at the time of dispensing for immunisation.
The medical professional adds the adjuvant
two single doses at least 3 weeks apart.
What Pandemrix contains
Active substance:
A/California/7/2009 (H1N1)v-like strain (X-179A)
Adjuvant:
Other ingredients:
http://tucksolutions.com/blog/tag/pandemic/
GSK's Pandemrix is a split-virion inactivated vaccine, produced in embryonated hens eggs . Split-virion vaccines contain virus that has been disrupted with detergent, and purified by centrifugation and diafiltration. The virus is inactivated with formaldehyde and sodium deoxycholate. In contrast to Celvapan, which contains no adjuvant, Pandemrix contains the adjuvant AS03, a squalene based oil-in-water emulsion. The vaccine is supplied in a two-vial format, one containing the antigen, the other the adjuvant. The adjuvant is added to the antigen vial at the time of dispensing for immunisation. The vaccine antigen is produced in Dresden, Germany.
*************
http://www.gsk.com/media/pressreleases/ ... _10089.htm
Pandemic (H1N1) 2009 Influenza Update: GSK's H1N1 'Pandemrix' vaccine receives positive opinion from European Regulators
************
http://justthevax.blogspot.com/2009/09/ ... or-us.html
GSK's Monovalent H1N1 Injectable: The The 2009 Monovalent H1N1 Vaccine is an inactivated split-virion vaccine (most likely) manufactured on the same platform as their Pandemrix vaccine, which incorporates the same manufacturing process as Fluarix .
GSK H1N1 vaccine is a split-virion influenza vaccine that will probably be formulated to contain 15 mcg hemagglutinin (HA) per 0.5-mL dose of the following virus strain: A/California/7/2009 (H1N1)v-like virus. The virus is propagated in fertilised hens' eggs. Each 0.5-mL dose also contains 0.120 mg octoxynol-10 (TRITON® X-100), 0.1 mg -tocopheryl hydrogen succinate, and 0.380 mg polysorbate 80 (Tween 80).
Each dose may also contain residual ( 0.0016 mcg) amounts of hydrocortisone, 0.15 mcg gentamicin sulfate, 1 mcg ovalbumin, 50 mcg formaldehyde, and 50 mcg sodium deoxycholate from the manufacturing process. It should be available in 0.5 mL single-dose, pre-filled syringes and contains no preservative (thimerosal). It may also be available in 5 mL multi-dose vials containing ten doses. Thimerosal (an ethylmercury derivative), is added as a preservative and each 0.5 mL dose contains 5 mcg (micrograms) of ethylmercury.
Indications and Usage: GSK H1N1 Monovalent Vaccine is indicated for active immunization of adults (18 years of age and older) against influenza disease caused by pandemic (H1N1) 2009 virus. Adults 18 years of age and older should receive a single 0.5 mL intramuscular dose.
****************
The European Medicines Agency (EMEA) has approved GlaxoSmithKline's " Pandemrix "
------------------------------------------
Sheri Nakken, R.N., MA, Hahnemannian Homeopath
http://www.wellwithin1.com/vaccine.htm & http://www.wellwithin1.com/homeo.htm
ONLINE/Email classes in Homeopathy; Vaccine Dangers; Childhood Diseases Reality
Next classes start December 2 & 3
bad to the bone
Sheri
http://www.emea.europa.eu/humandocs/PDF ... -17-en.pdf
GSK's proprietary adjuvant system AS03, (squalene-based oil-in-water emulsion)
NOTE: The adjuvant is added to the antigen vial at the time of dispensing for immunisation.
The medical professional adds the adjuvant
two single doses at least 3 weeks apart.
What Pandemrix contains
Active substance:
A/California/7/2009 (H1N1)v-like strain (X-179A)
Adjuvant:
Other ingredients:
http://tucksolutions.com/blog/tag/pandemic/
GSK's Pandemrix is a split-virion inactivated vaccine, produced in embryonated hens eggs . Split-virion vaccines contain virus that has been disrupted with detergent, and purified by centrifugation and diafiltration. The virus is inactivated with formaldehyde and sodium deoxycholate. In contrast to Celvapan, which contains no adjuvant, Pandemrix contains the adjuvant AS03, a squalene based oil-in-water emulsion. The vaccine is supplied in a two-vial format, one containing the antigen, the other the adjuvant. The adjuvant is added to the antigen vial at the time of dispensing for immunisation. The vaccine antigen is produced in Dresden, Germany.
*************
http://www.gsk.com/media/pressreleases/ ... _10089.htm
Pandemic (H1N1) 2009 Influenza Update: GSK's H1N1 'Pandemrix' vaccine receives positive opinion from European Regulators
************
http://justthevax.blogspot.com/2009/09/ ... or-us.html
GSK's Monovalent H1N1 Injectable: The The 2009 Monovalent H1N1 Vaccine is an inactivated split-virion vaccine (most likely) manufactured on the same platform as their Pandemrix vaccine, which incorporates the same manufacturing process as Fluarix .
GSK H1N1 vaccine is a split-virion influenza vaccine that will probably be formulated to contain 15 mcg hemagglutinin (HA) per 0.5-mL dose of the following virus strain: A/California/7/2009 (H1N1)v-like virus. The virus is propagated in fertilised hens' eggs. Each 0.5-mL dose also contains 0.120 mg octoxynol-10 (TRITON® X-100), 0.1 mg -tocopheryl hydrogen succinate, and 0.380 mg polysorbate 80 (Tween 80).
Each dose may also contain residual ( 0.0016 mcg) amounts of hydrocortisone, 0.15 mcg gentamicin sulfate, 1 mcg ovalbumin, 50 mcg formaldehyde, and 50 mcg sodium deoxycholate from the manufacturing process. It should be available in 0.5 mL single-dose, pre-filled syringes and contains no preservative (thimerosal). It may also be available in 5 mL multi-dose vials containing ten doses. Thimerosal (an ethylmercury derivative), is added as a preservative and each 0.5 mL dose contains 5 mcg (micrograms) of ethylmercury.
Indications and Usage: GSK H1N1 Monovalent Vaccine is indicated for active immunization of adults (18 years of age and older) against influenza disease caused by pandemic (H1N1) 2009 virus. Adults 18 years of age and older should receive a single 0.5 mL intramuscular dose.
****************
The European Medicines Agency (EMEA) has approved GlaxoSmithKline's " Pandemrix "
------------------------------------------
Sheri Nakken, R.N., MA, Hahnemannian Homeopath
http://www.wellwithin1.com/vaccine.htm & http://www.wellwithin1.com/homeo.htm
ONLINE/Email classes in Homeopathy; Vaccine Dangers; Childhood Diseases Reality
Next classes start December 2 & 3